Entering text into the input field will update the search result below

TG Therapeutics stock falls as FDA extends review of blood cancer drug combo

Mar. 03, 2022 11:42 AM ETTG Therapeutics, Inc. (TGTX)By: Ravikash, SA News Editor11 Comments

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

The U.S. Food and Drug Administration (FDA) extended the review date of TG Therapeutics' (TGTX -5.3%) applications seeking approval of ublituximab plus UKONIQ (umbralisib) to treat patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) to

Recommended For You

Comments (11)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Isn’t this exactly the same issue that blew their drugs for CLL out of the water?We were misinformed by the CEO at that the disparity in OAS was secondary to deaths from covid in immunocomprimised patients. I think it shows the FDA is incompetent at that it is very difficult to run any drug study during a pandemic where the patients are by definition, immunocompromised.
Arabian Horses profile picture
Clearly the FDA is incapable of completing a BLA on time as this is the umpteenth company facing this same issue. While COVID is serious and needs the attention of the FDA, so are other disease that need therapeutic options available. This response is becoming a broken record from the FDA. In 30 years I have not seen this much delay in approval for therapies. Nor have I seen the goal post repeatedly moved over and over again by the FDA.
They screwed up approving the new Alzheimer's drug and now they are going to screw with every new drug application to avoid having egg on their face once again.
FYI, if anyone thinks the FDA loves the industry they govern, you are wrong. In 30 years it is obvious that the FDA has no love loss for pharma/biotech.
We need new leadership and better reviewer. Those who can review new drug applications in the time frame they assign to the companies.
I have never been more disappointed and frustrated with the FDA.
@arabian horses it's a tough job and likely a thankless job. From the regulators's perspective all companies want their new drug submission approved so being objective and honest and fair/non biased, tough. Getting competent people tough. Hopefully TG's application given an unbiased assessment and judged on merit.
My email to a lot of TG staff are bouncing back. Looks like Titanic is going down?
Arabian Horses profile picture
@Crazinesscontinues So they are expected to talk to you about a product not approved by the FDA which is a felony. You must be shorting TG!
@arabian horses No! I bought TG long time ago...sold at $30....
Have been watching them closely.

I was emailing TG folks I saw at a conference...all emails bouncing back.

Never liked this company. Investor calls were always strange....CEO would abruptly stop people from making some comments. Insider....printing of money was also awful.

interesting to see how TG went down!!
LRNMO25 profile picture
The ODAC has now been scheduled for late Apr. FDA not in a real hurry here...Hope MS PDUFA goes smoother.
A conspiracy theorist would believe in outside (pharma competitor - Genentech) influence on the FDA with regards to TGTX. The MS drug is the key here. MS is a $10B+ pharma “industry.” Always follow the money.
First the FDA moves the goal posts then they issue more delays until maybe June. The FDA may not be incompetent, but they are certainly inefficient. Try running a cancer trial during a pandemic where immunocomprised individuals are at increased risk of dying from Covid 19. I do not think it should take 4 more months or possibly longer to review statistics
I’m buying more today this news is not really negative other than from a timeline perspective and also expected. MS is the key I am willing to wait for that catalyst later this year. Good luck to all investors.
@jeybolt00 Good job Mike.
TG is doomed!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.